---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052121"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:53:09.627962+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q1 2024 net loss $39.1M; cash $145.3M; positive diabetes clinical data

## Summary
- Net loss of $39.1M in Q1 2024 (incl. $5.0M stock comp) vs $29.1M in Q1 2023; R&D expenses rose to $33.8M.
- Cash, equivalents and restricted cash $145.3M at March 31, 2024, down from $177.2M at Dec 31, 2023.
- In type 2 diabetes COVALENT-111, 20%/36% of 100mg/200mg cohorts achieved durable HbA1c ≥1.0% reduction off therapy at 26 weeks.
- In type 1 diabetes COVALENT-112, first two patients showed improved beta-cell function (C-peptide Index) after BMF-219; well tolerated.
- Plan to report Week 26 data from >200 T2D patients (~40 T1D patients) in 2024; expect lower opex in H2 2024.

## SEC filing metadata
- accession: 0000950170-24-052121
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/0000950170-24-052121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/bmea-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052121
- JSON: https://secwatch.observer/filing/0000950170-24-052121.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052121.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000095017024052121/0000950170-24-052121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.